Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fosun Pharma Holds 20 Percent Shares In Tongjitang Chinese Medicines

This article was originally published in PharmAsia News

Executive Summary

As of June 19, Fosun has purchased a total of 6.765 million American Depository Shares in Tongjitang Chinese Medicines, making it the owner of 20.02 percent ordinary shares issued by the latter. Industry analysts have been speculating that Fosun wanted to force Tongjitang to delist from the U.S. market and consolidate its TCM assets. However, others believe the firm is unlikely to do that due to the substantial amount of time and money needed. Fosun has little revenue contribution from its TCM business although its profit margins from the sector can be as high as 70.4 percent, which explains its interest in Tonjitang. Fosun consistently adheres to its claim that the purchase is simply for investment purposes. (Click here for more - Chinese Language)

You may also be interested in...

BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.

Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts